Paula Lambert

Statistics

Publications

Citations

346

H-Index

Active since

2003

Affiliations

Vion Pharmaceuticals (United States)(Current)

Paula Lambert is an author at Vion Pharmaceuticals (United States) specializing in cancer pharmacology, clinical pharmacology, and oncology pharmacology.

Publications per year

2003–2004

Publications

Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion

Scott Wadler, Della Makower, Caroline Clairmont et al. · Journal of Clinical Oncology · 2004 · 146 citations

Medicine, Pharmacokinetics, Pharmacology +17

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

John R. Murren, Manuel Modiano, Caroline Clairmont et al. · PubMed · 2003 · 108 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

Francis J. Giles, Paula M. Fracasso, Hagop M. Kantarjian et al. · Leukemia Research · 2003 · 92 citations

Medicine, Pharmacology, Pharmacotherapy +5

1–3 of 3